Merck has shown consistent approach to their corporate social responsibility agenda in Africa and India since 2013

Merck has shown consistent approach to their corporate social responsibility agenda in Africa and India since 2013

The Merck Capacity Advancement Program was kicked off successfully in 7 sub- Saharan countries

NAIROBI, Kenya, October 21, 2014/ -- The Merck Capacity Advancement Program (http://www.merckgroup.com) aims at expanding the professional capacity in the areas of research and development, clinical research, supply chain integrity and efficiency, pharmacovigilance, community awareness and medical education for medical and pharmacy undergraduates, physicians and pharmacists in rural areas.

Logo: http://www.photos.apo-opa.com/plog-content/images/apo/logos/merck_logo.jpg

Photo 1: http://www.photos.apo-opa.com/index.php?level=picture&id=1456 (Rasha kelej , Vice president and head of Global Business Responsibility and Market Development at Merck Diabetes awarenes campaign in Luwerro)

Photo 2: http://www.photos.apo-opa.com/index.php?level=picture&id=1455 (Dr Frank Stangenberg Haverkamp receiving a trophy of appreciation by Kenya Minister of Health at Serena hotel)

The 5 year program was kicked off successfully in 7 sub- Saharan countries which are Kenya, Uganda, Namibia Angola, Ghana, Tanzania and Mozambique and will further expand to other Sub-Saharan and Asian countries in 2014.

 

Download the documentation: www.apo-mail.org/Merck-CAP-From-Africa-To-India.doc

 

Distributed by APO (African Press Organization) on behalf of Merck KGaA.

 

Media contact:

Elizabeth Njeri

[email protected]

SOURCE

Merck KGaA

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.